TSS
CRVS icon

Two Sigma Securities’s Corvus Pharmaceuticals CRVS Stock Holding History

Two Sigma Securities’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,384
Closed -$20.7K – 3000
2024
Q2 		$20.7K Buy
+11,384
New +$21.2K ﹤0.01% 2692
2023
Q4 		– Sell
-11,232
Closed -$16.4K – 3114
2023
Q3 		$16.4K Buy
+11,232
New +$23.8K ﹤0.01% 2606
2022
Q3 		– Sell
-11,355
Closed -$11K – 2677
2022
Q2 		$11K Buy
+11,355
New +$13.9K ﹤0.01% 2035
2021
Q4 		– Sell
-22,789
Closed -$110K – 1617
2021
Q3 		$110K Buy
+22,789
New +$67.5K ﹤0.01% 1297

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Securities's CRVS Position: Q3 2024 in Review

Two Sigma Securities sold out of Corvus Pharmaceuticals (CRVS) in Q3 2024, closing a stake of 11,384 shares — an estimated $20.7K sold.

Two Sigma Securities first reported a position in CRVS in Q3 2021 and held it in 4 quarters. The position peaked at $110K in Q3 2021. 62 funds tracked by Wall St. Rank hold CRVS as of Q3 2024.

  • Two Sigma Securities reported no remaining Corvus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Securities sold 11,384 Corvus Pharmaceuticals shares in Q3 2024, an estimated $20.7K.
  • Two Sigma Securities first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Two Sigma Securities's Corvus Pharmaceuticals position peaked at $110K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.